MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
21.90
+0.26 (+1.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close21.64
Open21.73
Bid21.25 x 900
Ask22.21 x 800
Day's range21.49 - 22.09
52-week range16.63 - 32.23
Volume3,871,079
Avg. volume6,093,306
Market cap11.303B
Beta (5Y monthly)1.73
PE ratio (TTM)243.33
EPS (TTM)0.09
Earnings date23 Feb 2020 - 27 Feb 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend date26 Jun 2007
1y target est25.88
  • Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

    Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

  • Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan
    Zacks

    Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

    The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.

  • Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
    Zacks

    Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down

    Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.

  • Theravance Pipeline Strong, Dependence on Yupelri a Concern
    Zacks

    Theravance Pipeline Strong, Dependence on Yupelri a Concern

    Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

  • Biogen Investors Face Next Test With Pending Drug Patent Ruling
    Bloomberg

    Biogen Investors Face Next Test With Pending Drug Patent Ruling

    (Bloomberg) -- Biogen Inc. investors should strap themselves in for a volatile week ahead of a key patent decision on its blockbuster multiple sclerosis drug.A decision from the U.S. Patent Trial and Appeal Board, expected by February 6, could move shares up or down by 8%, options expiring February 7 show. Implied volatility is elevated near 70%, which compares to a three-month historical average of 46%.Competitor Mylan NV is challenging a patent on the drug, Tecfidera, that could wipe out eight years of exclusivity for Biogen and bring a copycat drug to patients sooner than hoped. SunTrust analyst Robyn Karnauskas said a negative outcome for Biogen could slash the biotech’s discounted cash flow model by $40 per share, though specifics on Mylan’s commercial efforts are key to assessing the damage.The drug brought in $1.16 billion in sales for the final three months of 2019, with full-year revenue from the drug reaching $4.4 billion, roughly 30% of the company’s revenue. While bears have pointed out that a negative decision could impact sales in the near-term, William Blair analysts highlighted in a note to clients that any decision will likely be appealed, delaying a final ruling.Chief Financial Officer Jeff Capello told analysts Jan. 30 that the company would appeal any loss in either the patent office or district court cases, which would take 12 to 18 months. Capello said it is “difficult to predict” whether the generic-drug makers would launch without waiting for the appeals court decision.Decisions around Tecfidera patents “could provide near-term volatility and are extremely difficult to predict,” BMO Capital Markets analyst George Farmer wrote to clients. “Transitioning Tecfidera patients and initiating new patients to Vumerity, a more tolerable fumarate, would lessen the impact of a negative IPR decision, but the launch is too early to gauge demand.”Jefferies’ Michael Yee sees a bit more on the line for the decision, projecting a 10% move to either side for Biogen stock. He pointed out in a January 30 note that bears see Biogen as uninvestable ahead of the decision with bulls saying the ruling will remove an overhang on the stock.Among Biogen’s biggest fans on Wall Street, SVB Leerink, reiterated its outperform rating Monday morning writing that the current “valuation already reflects a worst case scenario for the Tecfidera loss of exclusivity.”The decision will pave the way for investors to bet on whether or not U.S. regulators will approve the company’s controversial Alzheimer’s drug candidate. Matt Phipps, an analyst at William Blair, highlighted that the patent ruling and the next steps for aducanumab are among the primary focuses for investors. Biogen is on pace to deliver a filing for the Alzheimer’s candidate sometime in the next two months.\--With assistance from Gregory Calderone, Susan Decker and Christopher Yasiejko.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Steven Fromm, Cristin FlanaganFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down
    Zacks

    Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down

    Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.

  • Why the Earnings Surprise Streak Could Continue for Mylan (MYL)
    Zacks

    Why the Earnings Surprise Streak Could Continue for Mylan (MYL)

    Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Should Value Investors Buy Mylan (MYL) Stock?
    Zacks

    Should Value Investors Buy Mylan (MYL) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Top Ranked Value Stocks to Buy for January 27th
    Zacks

    Top Ranked Value Stocks to Buy for January 27th

    Top Ranked Value Stocks to Buy for January 27th

  • New partnership aims to ease surging generic drug costs— by making its own
    Yahoo Finance

    New partnership aims to ease surging generic drug costs— by making its own

    A new partnership plans to bolster the U.S. supply of generic drugs, as part of a wide ranging effort to help drive down spiking costs and ease shortages.

  • Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?
    Zacks

    Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?

    While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.

  • Should Value Investors Consider Mylan N.V. (MYL) Stock?
    Zacks

    Should Value Investors Consider Mylan N.V. (MYL) Stock?

    Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.

  • S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
    Zacks

    S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF

    The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.

  • 10 Top-Ranked S&P 500 Stocks Outperforming in 2020
    Zacks

    10 Top-Ranked S&P 500 Stocks Outperforming in 2020

    The rally has been broad based and there are winners across various corners of the space.

  • Is Mylan (MYL) a Great Value Stock Right Now?
    Zacks

    Is Mylan (MYL) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Those Who Purchased Mylan (NASDAQ:MYL) Shares Five Years Ago Have A 64% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Mylan (NASDAQ:MYL) Shares Five Years Ago Have A 64% Loss To Show For It

    We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...

  • Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?
    Zacks

    Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?

    Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.

  • Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?
    Zacks

    Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?

    As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.

  • Pfizer's Braftovi sNDA Accepted by FDA for Priority Review
    Zacks

    Pfizer's Braftovi sNDA Accepted by FDA for Priority Review

    FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more